Can LTR Pharma’s Nasal Spray Revolutionize Treatment for Difficult-to-Swallow Patients?
LTR Pharma has partnered with Strategic Drug Solutions to co-develop OROFLOW®, a novel intranasal spray aimed at providing fast symptom relief for Oesophageal Motility Disorders, tapping into a growing $4.5 billion global market.
- Collaborative development agreement with Strategic Drug Solutions
- OROFLOW® targets Oesophageal Motility Disorders with rapid symptom relief
- Non-invasive nasal spray designed for patients with swallowing difficulties
- Global OMD market valued at $4.5 billion, projected to reach $8.1 billion by 2034
- Expands LTR Pharma’s pipeline into a new therapeutic area leveraging proprietary technology
A Strategic Partnership to Address a Critical Unmet Need
LTR Pharma Limited (ASX:LTP) has announced a significant collaborative development agreement with Strategic Drug Solutions, Inc. (SDS) to co-develop OROFLOW®, an innovative intranasal spray designed to treat Oesophageal Motility Disorders (OMD). These disorders, which impair the ability to swallow, affect millions globally and currently have limited non-invasive treatment options.
Building on its proprietary nasal spray platform, which has already yielded products like SPONTAN® and ROXUS® for erectile dysfunction, LTR Pharma is now venturing into a new therapeutic indication. The OROFLOW® program aims to provide rapid symptom relief, within approximately 10 minutes, offering a patient-friendly alternative to invasive procedures such as surgery or botulinum toxin injections.
Market Potential and Patient Impact
The global market for OMD treatments is substantial and expanding, valued at around $4.5 billion in 2024 and forecasted to grow to $8.1 billion by 2034, with a compound annual growth rate of 6.1%. The United States represents the largest share, followed by emerging opportunities in East Asia and other regions. Epidemiological data underscore the growing prevalence of OMDs, particularly achalasia and dysphagia, highlighting the pressing need for innovative therapies.
LTR Pharma’s Executive Chairman, Lee Rodne, emphasised the importance of this development: "OROFLOW represents an exciting expansion of our nasal spray platform. For patients with swallowing difficulties, oral medications present obvious challenges. Our nasal spray technology is designed to offer a patient-friendly solution that avoids the need to swallow medications, have surgery or undergo other problematic treatments while providing rapid symptom relief."
Early Stage but Promising Outlook
The collaboration is set to begin with Proof-of-Concept testing in the coming months, marking an important milestone for LTR Pharma’s growth strategy. While financial details remain undisclosed, the agreement solidifies a long-term partnership and broadens the company’s product pipeline into a new and promising therapeutic area.
As LTR Pharma leverages its proven intranasal delivery technology, the development of OROFLOW® could represent a meaningful advance in the treatment landscape for OMD patients, potentially improving quality of life for millions worldwide.
Bottom Line?
LTR Pharma’s move into OMD treatment with OROFLOW® signals a promising new chapter in non-invasive therapies.
Questions in the middle?
- What are the timelines and milestones for OROFLOW®’s clinical development and regulatory approval?
- How will LTR Pharma and SDS share commercial rights and revenues from this collaboration?
- What competitive advantages will OROFLOW® have against existing invasive and emerging OMD treatments?
